Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

NEXT STORY
Worldwide Medication Management System Industry to 2026 – Players Include AllScripts Healthcare Solutions, Siemens & General Electric Among Others
PREV STORY
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

NEXT STORY
Worldwide Medication Management System Industry to 2026 – Players Include AllScripts Healthcare Solutions, Siemens & General Electric Among Others
PREV STORY
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431

author_avatar
NASDAQ Market News

Marina Biotech Appoints Isaac Blech to its Board of Directors

City of Industry, CA , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. ...

author_avatar
NASDAQ Market News

Bioresorbable Polymers Market worth USD 3.15 billion by 2028, registering a CAGR of 14.1% – Report by Market Research Future (MRFR)

author_avatar
NASDAQ Market News